Summary
PhytoIntelligence 4.2.3 is a comprehensive technical specification and literature-triage methodology designed to grade phytochemical candidates against locked clinical indications. Authored by Marie-Soleil Seshat Landry of Landry Industries and the Marie Landry Spy Shop, this working draft establishes a rigorous epistemic framework governed by the 1=1=1 Axiom (Seshat's Axiom) and the Landry Hallucination-Free Protocol (LHFP-II). The document outlines a structured, reproducible approach to evaluating phytochemicals without emitting clinical formulations, dosing schedules, or efficacy claims. By enforcing live runtime provenance and strict verification rules, the framework ensures that unsupported claims, missing parameters, and unverified values immediately block dependent analytical gates, transforming potential dead-end runs into actionable research programs.
The document is organized into an authoritative specification followed by an executive summary and ten detailed condition dossiers covering conditions such as osteoarthritis, type 2 diabetes, major depressive disorder, and glioblastoma. The architecture operates through two explicit modes: Mode A for single-candidate triage and Mode B for user-specified combination evaluation. Mode A applies a seven-dimensional Diagnostic State Vector encompassing genomic, metabolic flux, redox, immune, epigenetic, kinetic, and developmental/reproductive toxicity dimensions. Candidates are evaluated using tiered evidence weights ranging from randomized controlled trials down to in-silico predictions, alongside conflict-of-interest factors and rigorous safety gates including a pre-aggregation developmental toxicity veto and an adverse event risk score.
A central focus of the specification is the mathematical modeling of the Composite Evidence Score and its integration with feasibility and interaction risk gates. The D-3 dose-feasibility gate evaluates dimensionless free trough exposure ratios against pre-registered thresholds using typed source values, while the interaction risk gate systematically screens candidates against standard-of-care clearance pathways and pharmacodynamic interactions. Version 4.2.3 introduces vital patches, including conservative interval propagation for source-magnitude bounds and ranking robustness, as well as mechanism-overlap diagnostics. The framework openly addresses historical defects, such as the transition from flawed mass allocation models to the Measurement Manifest, which prioritizes bench tasks for blocked runs based on effort units and unblocked gates.
The ten example condition outputs demonstrate the practical application of the methodology across diverse therapeutic areas, illustrating why candidate compounds successfully clear gates or face exclusion due to systemic exposure shortfalls, safety vetoes, or drug-interaction liabilities. For example, in the evaluation of basal cell carcinoma, compounds like cyclopamine and curcumin are rigorously filtered, leaving sulforaphane as a ranked survivor accompanied by a prioritized measurement manifest. Similar rigorous triage processes are detailed for metabolic, neurological, inflammatory, and oncological conditions, providing clear transparency into the decision-making criteria enforced by the reference engine and its accompanying conformance test suite.
Researchers, pharmacologists, and computational scientists investigating phytochemical hypotheses will find this specification essential for maintaining methodological integrity and reproducibility. The document provides complete technical transparency, including canonical SHA-256 hashing specifications for analytic plans and Epistemic Fingerprints, reference implementation notes for Python verification modules, and explicit disclaimers regarding the boundary between literature triage and clinical validation. By defining clear rules for analyst reliability, sign disagreement adjudication, and version control, PhytoIntelligence 4.2.3 offers a robust standard for rigorous phytochemical evaluation.
Ultimately, PhytoIntelligence 4.2.3 serves as a definitive blueprint for conducting transparent, auditable, and falsifiable phytochemical triage. It bridges the gap between raw scientific literature and structured hypothesis generation while strictly respecting safety boundaries and clinical standards of care. Readers are provided with both the conceptual rationale and the mathematical formalisms required to execute conforming evaluations, ensuring that every research hypothesis generated by the framework is fully traceable, rigorously tested, and grounded in verifiable empirical evidence.
FAQ
What is the primary purpose of PhytoIntelligence 4.2.3?
It is a literature-triage and hypothesis-prioritisation methodology that grades phytochemical candidates against a locked clinical indication, resulting in a ranked hypothesis dossier and measurement manifest without emitting formulations or dosing schedules.
What does the 1=1=1 Axiom entail?
Seshat's Axiom treats truth data as an identity loop where Observation equals Replication equals Realization, requiring all published claims to satisfy the Landry Hallucination-Free Protocol.
How does Mode A differ from Mode B?
Mode A performs single-candidate triage using data such as DSV vetoes, CES scores, dose feasibility, and interaction risks. Mode B evaluates user-specified sets of two or more candidates that have cleared Mode A, applying additional pharmacokinetic alignment, synergy, and safety index gates.
What happens when a candidate fails a gate?
The run halts or the candidate is excluded based on the specific gate rules, and the framework generates a prioritized Measurement Manifest to convert the blocked run into a structured research program.
Does PhytoIntelligence 4.2.3 provide clinical dosages or treatment protocols?
No. The framework explicitly refuses to emit milligram allocations, dosing schedules, treatment protocols, or efficacy claims, functioning strictly as an adjunct research hypothesis generator.
